|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutation incidence was significantly lower in adenocarcinoma (2/135, 1.5%) than in squamous cell carcinoma (5/77, 6.5%, p=0.0495).
|
16930767 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations and amplification are detected in 1% of primary lung adenocarcinomas (ADCs) and in 38% of primary lung squamous cell carcinomas.
|
27007084 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In tumor types with more than 10 patients tested, PIK3CA mutations were most frequent in endometrial (3 of 14, 21%), ovarian (5 of 30, 17%), colorectal (9 of 54, 17%), breast (2 of 14, 14%), cervical (2 of 15, 13%), and squamous cell cancer of the head and neck (1 of 11, 9%).
|
21216929 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, blocking the whole PI3K-AKT-mTOR pathway with the PI3K/mTOR dual inhibitor BEZ235 also showed efficacy in treating this subtype of lung SqCC.
|
26216950 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Whether they function as direct precursors to a less common form of squamous cell carcinoma will require further study, but carcinomas associated with these lesions might warrant testing for PIK3CA mutations to address this question.
|
27834349 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations were preferentially detected in patients with adenocarcinomas, and the frequency of PIK3CA mutations in patients with squamous cell carcinomas was higher than that in patients with other histological cancer types.
|
31757465 |
2020 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 675 tumors revealed activation of PIK3CA and other PI3K/AKT pathway genes in 31% of squamous carcinomas and 24% of adeno- and adenosquamous tumors, predominantly at two sites (E542K, E545K) in the helical domain of the PIK3CA gene.
|
26080840 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ΔNp63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).
|
23196793 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After SCC transformation, the absence of G45 domain in DeltaG45 cells was associated with deficient extracellular signal-regulated kinase and phosphotidylinositol 3-kinase (PI3K) pathway activation, impaired invasion, deficient metalloproteinase activity, and absent tumorgenicity in vivo.
|
18413757 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transformed SCC acquired genomic alterations related to the PI3K/AKT/mTOR pathway, in addition to the initial EGFR mutation.
|
31319998 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification.
|
12796399 |
2003 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The knowledge of the PIK3CA's involvement in OSCC is important because a specific kinase inhibitor could be considered as a future therapeutic option for OSCC patients with PIK3CA mutations.
|
21824802 |
2011 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We have studied the prognostic importance of PIK3CA mutations as well as the relation to other markers in a large number of early stage lung cancers of squamous carcinoma subtype.
|
28024696 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We therefore screened 61 non-melanoma skin cancer samples (30 SCC and 31 BCC) for the presence of activating PIK3CA and AKT1 mutations.
|
20557351 |
2010 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
|
18097548 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations were more common in squamous cell carcinomas than in non-squamous cell tumors (15.3% vs 7.3%, of P < 0.01).
|
26358014 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC.
|
22768234 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001).
|
26197069 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutations in head and neck squamous cell carcinoma.
|
16533766 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with adenocarcinoma had fewer PIK3CA mutations (14%), and survived longer (median, 14.2 months) than those with squamous cell carcinoma (48% and 7.2 months; p = 0.016, and 0.001, respectively).
|
25426553 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This may be because pathways enriched in the TrkB high expressers, like those involving oncogenes NFE2L2, PIK3CA, and SOX2, are known to have SCC anatomic site-specific effects on progression.
|
31221127 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the TP53 gene and to lesser extent in the PIK3CA gene seem more frequent in cervical adenocarcinoma than in squamous cell carcinoma and CIN3.
|
25220666 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA-mutated NSCLC represents a clinically and genetically heterogeneous subgroup in adenocarcinomas as well as in squamous cell carcinomas with a higher prevalence of these mutations in sqamous cell carcinoma.
|
25473901 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation was found in 3.9% of squamous cell carcinoma and 2.7% of adenocarcinoma.
|
24533074 |
2014 |